Lightnews — Scholar-powered news

LightNews

ASH Clinical News

@ashclinicalnews.bsky.social

200 followers 4 following 70 posts

A magazine from @ash-hematology.bsky.social offering news and views for the broader hematology/oncology community. www.ASHClinicalNews.org

Posts Media Videos Starter Packs

ASH Clinical News @ashclinicalnews.bsky.social · 1d

In patients newly diagnosed with #MultipleMyeloma #MMsm and #transplant eligible, treatment with an induction regimen of #IsaKRD resulted in the highest rates of pretransplant MRD negativity reported to date at 66% at 10⁻⁵ and 50% at 10⁻⁶: ow.ly/8euE50Xbhiy
#HemeSky #OncSky #myeloma

Quadruplet Induction Therapy for MM Achieves High Rate of MRD Negativity in MIDAS Trial | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 2d

A recent cohort study on #clonal #hematopoiesis of indeterminate potential (CHIP) has demonstrated that it may modestly increase the risk of #VenousThromboembolism (VTE), as 4.5% of CHIP carriers experienced a #VTE, compared with 3.2% of noncarriers: ow.ly/5mZR50Xb0EX
#HemeSky #thrombosis

Study Shows Modest Increased Risk of VTE in Patients With CHIP | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 6d

#AI Assurance: AI-generated health information may be considered more trustworthy than expected. According to a national survey, 63% of Americans think AI-generated #health information is somewhat or very reliable.
#HemeSky #MedSky

ASH Clinical News @ashclinicalnews.bsky.social · 7d

Bridging therapy with #talquetamab enabled patients with high-risk #myeloma #MMsm to successfully transition to #BCMA #CARTcell therapy, with 88% experiencing rapid disease control and proceeding to treatment with ide-cel or cilta-cel: ow.ly/7JkM50X8KYa
#HemeSky #MyelomaSky #MultipleMyeloma

Talquetamab Bridging Therapy Enables Transition to BCMA CAR-T for Patients With High-Risk Myeloma | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 8d

The October issue is out now! Highlights include a feature on recent technological advancements in #hematopathology, results on quad induction therapy for #MMsm and intermediate dose #cytarabine post-induction in #AML, and more. See the full lineup here: ow.ly/rfTn50X81bG
#HemeSky #OncSky

ASH Clinical News @ashclinicalnews.bsky.social · 12d

An analysis of #genomic data from patients with #MultipleMyeloma #MMsm showed that loss of #CD38 expression can occur after treatment with #antiCD38 antibodies, arising in 20% of patients analyzed, with three cases exhibiting a loss of both copies: ow.ly/IfmE50WXc76 #HemeSky #OncSky

Study Identifies CD38 Mutations That Confer Resistance to CD38-Targeting Antibodies in Patients with Multiple Myeloma | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 13d

Patients who received #cyclosporin and #cyclophosphamide for #GVHD prevention after #HCT had improved outcomes compared to those receiving the standard cyclosporin and #methotrexate, with a median GRFS of 26.2 months vs. 6.4 months: ow.ly/pOA250WXckE #HemeSky #HemeOnc

Cyclosporin-Cyclophosphamide Performs Well for GVHD Prevention After Transplant | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 16d

Explore the benefits and risks of aggressive vs. non-aggressive MCL treatment strategies in our expert-led session, Fri. Oct. 3. Secure your spot today. #HemeSky #HemeOnc bit.ly/4nWEIli

ASH Clinical News @ashclinicalnews.bsky.social · 17d

Findings from the BASIS trial reveal that #marstacimab is an effective prophylactic option for patients with #hemophilia A and B, as the therapy led to a 92% reduction in mean ABR among patients who previously received on-demand #clotting factors: ow.ly/RIy850WXbGs #HemeSky #hemostasis

Marstacimab Provides New Prophylactic Option for Hemophilia A, B | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 21d

The IMS-IMWG recently released new recommendations on the definition of high-risk #MultipleMyeloma, based on the use of genomic tools, to improve identification of patients with high-risk #MMsm and allow clinicians to provide more realistic prognoses: ow.ly/lfv350WXaup #HemeSky #OncSky

IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 22d

See what's to come in the October issue with @aarongerds.bsky.social! Issue highlights include a clinical case of a patient with a large #hematoma and multiple comorbidities, an in-depth look at the rare #WHIMsyndrome, the evolution of #hematopathology, and more: ow.ly/nYsx50WXxqA #HemeSky #MedSky

ASH Clinical News: October 2025 From the Desk Of...

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

ASH Clinical News @ashclinicalnews.bsky.social · 24d

In #Uruguay, use of a single-run NGS approach was able to detect both somatic mutations and copy number variants in patients with #MyelodysplasticSyndromes #MDS, ultimately allowing for both improved diagnostic accuracy and optimized workflows: ow.ly/Cfwx50WX9KG #HemeSky #HemeOnc

Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 28d

In patients with treatment-naïve #CLL, MRD-guided therapy with #ibrutinib plus #venetoclax led to greater rates of undetectable MRD, extended PFS, and increased OS than ibrutinib alone or #chemoimmunotherapy, especially among patients with unmutated IGHV: ow.ly/oA2u50WWZZc #HemeSky #HemeOnc

Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · 29d

Pregnancy Outcomes in SCT: Urinary tract infection (UTI) in #pregnancy may be influenced by #SickleCell trait (SCT). A retrospective data analysis found that 11.7% of patients with SCT and 7.1% of patients without SCT experienced #UTI.
#HemeSky #Hematology

ASH Clinical News @ashclinicalnews.bsky.social · Sep 15

Phase III data indicate that #avatrombopag is an effective oral treatment for #pediatric patients with a confirmed diagnosis of #ImmuneThrombocytopenia #ITP, with 28% and 81% of patients meeting the primary and alternative primary endpoints, respectively: ow.ly/v9N250WWMEp
#HemeSky #hemostasis

Phase IIIb Results Show Avatrombopag to Be Safe, Effective Treatment for Children With ITP | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · Sep 12

Transparency Unlocked: Transparency of the #FDA approval process may be increasing. Recently, the FDA made more than 200 complete response letters highlighting safety and efficacy concerns accessible to the public.
#HemeSky #MedSky

ASH Clinical News @ashclinicalnews.bsky.social · Sep 10

The #FDA recently approved #linvoseltamab for the treatment of R/R #MultipleMyeloma #MMsm in adult patients who have received four or more prior lines of therapy following results from the LINKER-MM1 trial, which found a 70% ORR and a 45% CR rate: ow.ly/y8pA50WTRxC
#HemeSky #OncSky #Oncology

FDA Approves Linvoseltamab for R/R MM | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · Sep 9

Despite findings from the phase III STARGLO study showing an improvement in OS, a CR letter issued by the #FDA stated there was not sufficient evidence to support a proposed second-line indication of #glofitamab-gxbm for R/R transplant-ineligible #DLBCL: ow.ly/8YWU50WTR3K
#HemeSky #OncSky

PDUFA Pending Update: Glofitamab-gxbm in R/R DLBCL | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · Sep 5

According to new long-term data, among patients with advanced-stage, asymptomatic low-tumor-burden #FollicularLymphoma, early #rituximab monotherapy delayed the TTNT to more than 15 years, compared with less than six years seen with watchful waiting: ow.ly/luEa50WRTVZ
#HemeSky #lymphoma #HemeOnc

Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · Sep 4

The September issue is out now! Highlights include features on the clinician's role in #patient support groups, #marstacimab #prophylaxis for #hemophilia A and B, and post-transplant cyclosporin-cyclophosphamide for #GVHD prevention. See the full lineup: ow.ly/q4zr50WQGOT

ASH Clinical News @ashclinicalnews.bsky.social · Sep 2

APPs on the Front Lines: #AdvancedPracticeProviders (APPs) are an integral part of the #healthcare workforce. A recent report found that APPs make up 40.6% of the health care workforce. The report noted that APPs and #physicians may soon make up equal parts of the labor force.
#HemeSky #MedSky

ASH Clinical News @ashclinicalnews.bsky.social · Aug 27

See what's to come in the next issue! Below,
@aarongerds.bsky.social shares issue highlights, including a look at the clinician's role within patient support groups, the link between #GLP1s and #hematologic diseases, the growth of #hematology in #Pakistan, and more 🩸
www.youtube.com/watch?v=bsOB...

ASH Clinical News: September 2025 From the Desk Of...

YouTube video by American Society of Hematology

www.youtube.com

ASH Clinical News @ashclinicalnews.bsky.social · Aug 26

Subcutaneous #isatuximab delivered via an on-body injector was found to be noninferior to IV isatuximab plus #pomalidomide and #dexamethasone in patients with R/R #MultipleMyeloma #MMsm, with both methods resulting in comparable ORR and 12-month PFS: ow.ly/zJCh50WM6cl
#HemeSky #MyelomaSky #HemeOnc

Subcutaneous Isatuximab Noninferior to IV Administration in R/R MM | ASH Clinical News | American Society of Hematology

ASH Clinical News @ashclinicalnews.bsky.social · Aug 22

Importing Inflation: The proposed U.S. #tariff on #pharmaceutical imports would drive up costs immensely. An analysis revealed that the 25% tariff is expected to increase #drug costs by $51 billion annually and drive up prices by as much as 12.9%.
#HemeSky #MedSky

ASH Clinical News @ashclinicalnews.bsky.social · Aug 18

According to a first-in-human study, administration of huCART19-IL18, a fourth-generation #cytokine-secreting CD19 #CARTcell therapy, showed initial efficacy in patients with R/R #lymphoma, with 81% of patients achieving a partial or complete response: ow.ly/HME950WHw1F
#HemeSky #HemeOnc #OncSky

Cytokine-Secreting CAR T-Cell Candidate Therapy Shows Preliminary Efficacy in Patients With Lymphoma | ASH Clinical News | American Society of Hematology